Head of Early Clinical Development
Schrodinger
Dr. Daniel Weiss, MD, CPI is currently the VP and Head of Early Clinical Development at Schrodinger, Inc. where he is responsible for the functions of clinical sciences, clinical operations and regulatory sciences. Daniel earned his MD from Rutgers New Jersey Medical School, completed his Emergency Medicine residency at Drexel College of Medicine and worked for a number of years as a Board Certified Emergency Medicine physician before transitioning to a dedicated career in pharmaceutical drug development. Daniel is also a Certified Principal Investigator having worked as a principal Investigator within a busy 150 bed clinical pharmacology unit. Daniel has held previous positions as a clinical pharmacologist within Celgene's Department of Clinical Pharmacology, as a study physician within Celgene's clinical oncology development group and as a study physician leading science and strategy to demonstrate early proof of concept for oncology and rare disease assets for Chugai's US operations. Having survived two battles of head and neck cancer, Dan is passionate about incorporating patient centricity into clinical drug development so that the patient's perspective is at the forefront of drug development.
Disclosure information not submitted.
Thursday, May 12, 2022
8:00 AM – 12:00 PM ET
.png)